Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorGroupe Hospitalier Diaconesses Croix Saint-Simon

About this trial

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

Eligibility criteria

Qualifiers

Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to be performed in patients with pleural effusion.

Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion

Age ≥18 and < 75 years old.

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score < 6 in patients > 70 years old).

Disqualifiers

FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion.

Patient having received previous chemotherapy for ovarian cancer.

Left ventricular ejection fraction < 50% before chemotherapy initiation

Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted)

Trial design

Treatments tested in this trial

  • CC0 - Carboplatin (IV) - Paclitaxel (IV)
  • CC0 - Cisplatin (IP) - Epirubicin (IV)
  • CC>0 - Carboplatin (IV)- Paclitaxel (IV)
  • CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)

Treatment groups

84 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Groupe Hospitalier Diaconesses Croix Saint-Simon

Lead sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborator